Developer docs
API playgroundTry for free, no card

Search company profiles

GENFIT

Full company profile

uuid0002kjo

Namestring
GENFIT
Legal namestring
GENFIT SA
Websiteurl
genfit.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

GENFIT SA is a late-stage biopharmaceutical company headquartered in Loos, France (near Lille), founded in 1999 by Jean-Fran\u00e7ois Mouney. Listed on Euronext Paris under ticker GNFT (and previously on Nasdaq until a voluntary delisting in November 2025), GENFIT employs 150+ people across offices in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The company focuses exclusively on rare and life-threatening liver diseases where there are few or no approved therapies, and combines in-house drug discovery, clinical development, regulatory affairs and non-invasive diagnostics expertise.

The commercial engine is Iqirvo (elafibranor), an oral dual PPAR \u03b1/\u03b4 agonist discovered and developed internally by GENFIT that received Accelerated Approval from the FDA, EMA and UK MHRA in 2024 for Primary Biliary Cholangitis (PBC) and is commercialized worldwide by Ipsen under a 2021 exclusive licensing deal. Beyond Iqirvo, the R&D portfolio comprises eight programs across multiple stages of development: in ACLF and hepatic encephalopathy, NTZ/G1090N (nitazoxanide reformulation with FDA Orphan Drug Designation), SRT-015 (licensed ASK1 inhibitor), CLM-022 (licensed NLRP3 inflammasome inhibitor) and VS-02-HE (urease inhibitor); in other life-threatening indications, GNS561 (PPT-1 inhibitor for KRAS-mutated cholangiocarcinoma, in Phase 1b/2a) and VS-01-HAC (liposomal platform for hyperammonemic crises in urea cycle disorders, FDA Rare Pediatric Disease designation); and in diagnostics, NIS4/NIS2+ blood-based biomarker algorithms for at-risk NASH/MASH (commercially available via Labcorp as NASHnext) plus a prototype TS-01 point-of-care ammonia device. The portfolio is backed by 1,000+ patents.

GENFIT monetizes primarily through licensing royalties and milestone payments rather than direct sales. FY2025 revenue was \u20ac65.4 million, comprised of \u20ac21.8 million in royalties on Ipsen's $208 million of Iqirvo net sales and \u20ac43.6 million in milestone payments (including a \u20ac17 million performance milestone and a \u20ac26.5 million Italy pricing/reimbursement milestone). Go-to-market is via channel partners: Ipsen for Iqirvo commercialization globally and Labcorp for the NIS4/NASHnext diagnostic. The company held \u20ac101.1 million in cash at year-end 2025 (\u20ac136.1 million as of March 31, 2026 after activating an additional \u20ac30 million HCRx royalty-financing tranche in January 2026), with stated cash runway extending beyond end of 2028 despite an \u20ac86.0 million FY2025 net loss driven in part by a \u20ac46.2 million non-cash impairment tied to the September 2025 discontinuation of the VS-01 ACLF program.

Short descriptiontext

GENFIT SA is a France-based, Euronext Paris-listed biopharmaceutical company that develops therapies and diagnostics for rare and life-threatening liver diseases, generating revenue primarily through royalties and milestones from Ipsen's commercialization of Iqirvo (elafibranor) for Primary Biliary Cholangitis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLoos, France
HQ citystring
Loos
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liver disease therapeutics, rare disease biopharmaceuticals, non-invasive diagnostics, biomarker algorithm testing, clinical stage drug development
Industry3 codes
PRIMARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Liver Disease Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Royalties from Iqirvo Sales
TypeLicensing Royalties
Description

GENFIT receives royalty revenue from Ipsen's sales of Iqirvo (elafibranor) for Primary Biliary Cholangitis. In 2025, royalty revenue was €21.8 million, up from €2.7 million year-over-year.

globenewswire.com
2Milestone Payments
TypeLicensing Royalties
Description

One-time payments triggered by clinical, regulatory, or commercial milestones. In 2025, GENFIT received €43.6 million in milestone payments, including a €17 million milestone triggered by Ipsen's strong Iqirvo performance, and a €26.5 million milestone for pricing/reimbursement approval in Italy.

globenewswire.com
3Royalty Financing Agreement
TypeLicensing Royalties
Description

GENFIT activated an additional €30 million tranche under its royalty-financing agreement with HCRx in January 2026, extending cash runway beyond end of 2028.

globenewswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NIS4
Description

Non-invasive blood-based molecular diagnostic technology for identifying patients with at-risk NASH/MASH with NAS≥4 and significant fibrosis F≥2

genfit.com
+3 more records
Core offering1 text field

GENFIT is a biopharmaceutical company that discovers, develops, and commercializes therapeutic drug candidates and non-invasive diagnostic technologies for rare and life-threatening liver diseases. Its commercial offering includes Iqirvo (elafibranor), a dual PPAR α/δ agonist approved for Primary Biliary Cholangitis in 2024 and marketed by Ipsen, plus the NIS4/NIS2+ blood-based diagnostic biomarkers for NASH/MASH identification (commercialized as NASHnext via Labcorp). The development pipeline targets Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma, urea cycle disorders, and hepatic encephalopathy through multiple proprietary mechanisms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Iqirvo generated $208M in net sales by Ipsen in 2025, triggering $20M milestone payment to GENFIT one year ahead of schedule
+3 more records
Product overview1 text field

GENFIT is a biopharmaceutical company focused on rare, life-threatening liver diseases. Its product portfolio comprises therapeutic drug candidates across multiple development stages and a diagnostic franchise. The therapeutic pipeline includes Iqirvo® (elafibranor), a dual PPAR α/δ agonist for Primary Biliary Cholangitis (PBC) now commercialized by Ipsen following FDA/EMA/MHRA approval in 2024, and multiple investigational programs for ACLF and associated conditions: G1090N (NTZ reformulation), SRT-015 (ASK1 inhibitor), CLM-022 (NLRP3 inflammasome inhibitor), and VS-02-HE (urease inhibitor for hepatic encephalopathy), all in preclinical or early clinical stages. The diagnostics franchise includes NIS4® and NIS2+®, non-invasive blood-based biomarker technologies for identifying at-risk NASH/MASH patients (commercially available as NASHnext® via Labcorp), and TS-01, a prototype point-of-care device for blood ammonia measurement. Additional therapeutic programs target cholangiocarcinoma (GNS561 in Phase 1b/2a) and urea cycle disorders (VS-01-HAC in preclinical). The company's pipeline covers eight programs across ACLF, other life-threatening indications, and diagnostics.

Product and service10 records
1Iqirvo (elafibranor)
CategoryApproved therapeutic product
Description

A dual PPAR α/δ agonist originally discovered and developed by GENFIT for treatment of Primary Biliary Cholangitis (PBC). Received Accelerated Approval from FDA, EMA, and MHRA in 2024 and is commercialized by Ipsen in the US and several European countries under a global licensing agreement.

2NIS4
CategoryDiagnostic product
Description

First-generation blood-based molecular diagnostic technology integrating four NASH/MASH-associated biomarkers (alpha-2-macroglobulin, YKL-40, hemoglobin A1c, miR-34a-5p) through an algorithm to produce a single score for identifying patients with at-risk NASH/MASH. Commercially available as NASHnext via Labcorp.

3NIS2+
CategoryDiagnostic product
Description

Optimized blood-based molecular diagnostic technology demonstrating robust improved clinical performance for efficient identification of at-risk NASH/MASH regardless of patient characteristics such as age, sex, and type 2 diabetes.

4TS-01
CategoryDiagnostic device prototype
Description

Point-of-care diagnostic device based on transmembrane pH-gradient polymersome technology for at-home measurement of ammonia in blood, designed to be fast, selective, and sensitive across a wide range covering physiological and pathological ammonia levels.

5G1090N (NTZ reformulation)
CategoryInvestigational therapeutic program
Description

A new reformulation of nitazoxanide (NTZ) being developed for Acute-on-Chronic Liver Failure (ACLF), with anti-inflammatory and anti-apoptotic properties targeting gut microbiota and bacterial overgrowth, designed to optimize dose-response and provide dosing flexibility for ACLF patients with renal or hepatic impairment.

6SRT-015
CategoryInvestigational therapeutic program
Description

An ASK1 (Apoptosis Signal-Regulating Kinase 1) inhibitor with injectable formulation licensed exclusively worldwide from Seal Rock Therapeutics in May 2023 for acute liver disease including ACLF. Preclinical and clinical evidence supports multi-system benefits including blocking hyper-inflammatory response, reducing ROS-related immune response, reducing apoptosis, and protecting macrophages.

7CLM-022
CategoryInvestigational therapeutic program
Description

A first-in-class NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome inhibitor licensed exclusively worldwide from Celloram Inc. in July 2023 for liver disease applications, showing promise in animal models for reducing liver damage and inflammation.

8VS-02-HE
CategoryInvestigational therapeutic program
Description

A hydroxamic acid derivative designed as a urease inhibitor to treat Hepatic Encephalopathy (HE), a common complication of ACLF, developed as a unique oral and colon-active formulation designed to minimize systemic absorption of ammonia and reduce glutamine levels in the brain.

9VS-01-HAC
CategoryInvestigational therapeutic program
Description

A liposomal therapeutic candidate based on proprietary scavenging liposomal technology administered directly into the peritoneal cavity following drainage of ascites, being developed as a potential first-line lifesaving treatment for acute hyperammonemic crises associated with Urea Cycle Disorders (UCD) and Organic Acidemias (OA). Granted Rare Pediatric Disease designation by the FDA.

10GNS561 in CCA
CategoryInvestigational therapeutic program
Description

A Palmitoyl Protein Thioesterase-1 (PPT-1) inhibitor in-licensed from Genoscience Pharma in 2021 that blocks cancer cell proliferation by inhibiting late-stage autophagy, being evaluated in a Phase 1b/2a trial combined with trametinib for KRAS-mutated cholangiocarcinoma. FDA Orphan Drug Designation obtained.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1EF CLIF
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Co-hosting annual ACLF Insights event at EASL Congress 2026. Collaboration on landmark global consensus meeting to forge unified definition of ACLF.

globenewswire.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-07-01
Description

Exclusive worldwide licensing of CLM-022, a first-in-class NLRP3 inflammasome inhibitor for liver disease applications.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-05-01
Description

Exclusive worldwide licensing of SRT-015 (ASK1 inhibitor) for injectable formulation in acute liver disease including ACLF treatment (21 consecutive days or less).

4Versantis AG
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

Acquisition completed in 2022 for CHF 40 million upfront (~$41 million) plus up to CHF 65 million in milestones. Swiss clinical-stage biotech focused on liver diseases, bringing VS-01 liposomal technology and VS-02 urease inhibitor programs. Total potential deal value of CHF 105 million.

startupticker.ch
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-17
Description

Exclusive global licensing agreement for elafibranor (Iqirvo) for Primary Biliary Cholangitis. Ipsen commercializes the drug in the US, Europe, and other markets. Ipsen also became an 8% shareholder in GENFIT in 2021. Ipsen initiated the only global Phase 3 trial (ELASCOPE2) for PSC in February 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Agreement to commercialize NASHnext, powered by GENFIT's proprietary NIS4 diagnostic technology for identifying at-risk NASH/MASH.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Exclusive licensing of GNS561 (PPT-1 inhibitor) for cholangiocarcinoma treatment. GNS561 blocks cancer cell proliferation by inhibiting late-stage autophagy.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage biopharma focused on MASH with lead asset pegozafermin (FGF21 analog) in Phase 3. Comparable in therapeutic-area focus and size to GENFIT, with similar specialization in liver metabolic diseases.

TypeDirect peer
Description

French late-stage clinical biopharmaceutical company developing therapeutics for liver diseases, including lead asset lanifibranor for MASH. Direct fellow French liver-focused biotech comparable in size, stage, and therapeutic-area focus to GENFIT.

TypeDirect peer
Description

Maker of Ocaliva (obeticholic acid), the first FDA-approved therapy for Primary Biliary Cholangitis. Direct competitor to GENFIT's Iqirvo in PBC with similar orphan-liver-disease positioning.

TypeDirect peer
Description

US biopharma that developed Rezdiffra (resmetirom), the first FDA-approved therapy for MASH with moderate-to-advanced fibrosis. Direct peer in the hepatology space and overlapping biomarker/diagnostic themes relevant to NIS4/NIS2+.

TypeBroad incumbent
Description

Global biopharmaceutical leader with broad hepatology presence, including recent acquisition of CymaBay Therapeutics (seladelpar for second-line PBC). Competes broadly with GENFIT in liver disease and now markets a direct PBC competitor to Iqirvo.

TypeBroad incumbent
Description

Global specialty biopharma that is GENFIT's commercialization partner for Iqirvo and an 8% shareholder. Operates a broader hepatology and rare-disease portfolio (including Albireo) overlapping GENFIT's PBC and ACLF focus.

TypeEmerging player
Description

Clinical-stage biopharma developing oral therapies for MASH and other chronic liver diseases. Overlaps with GENFIT's hepatology and biomarker-based diagnostic positioning, addressing similar fibrotic and metabolic liver indications.

TypeEmerging player
Description

Clinical-stage biopharma focused on integrin-based therapies for fibrotic diseases including liver fibrosis and PSC, intersecting with GENFIT's liver fibrosis and cholestatic disease focus.

TypeEmerging player
Description

European clinical-stage biopharma developing therapeutics for hepatitis B and acute liver diseases. Comparable in size and European origin to GENFIT, addressing overlapping liver disease therapeutics.

TypeOthers
Description

Independent global rare-disease biopharma with a similar 'small commercial-stage plus specialty pipeline' business model and focus on orphan drug commercialization. Comparable as a strategic model archetype for GENFIT's pursuit of rare-disease and orphan pricing economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GENFIT

Liver Disease Biopharmaceuticalsgenfit.com

GENFIT SA is a France-based, Euronext Paris-listed biopharmaceutical company that develops therapies and diagnostics for rare and life-threatening liver diseases, generating revenue primarily through royalties and milestones from Ipsen's commercialization of Iqirvo (elafibranor) for Primary Biliary Cholangitis.

What GENFIT does

GENFIT SA is a late-stage biopharmaceutical company headquartered in Loos, France (near Lille), founded in 1999 by Jean-Fran\u00e7ois Mouney. Listed on Euronext Paris under ticker GNFT (and previously on Nasdaq until a voluntary delisting in November 2025), GENFIT employs 150+ people across offices in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The company focuses exclusively on rare and life-threatening liver diseases where there are few or no approved therapies, and combines in-house drug discovery, clinical development, regulatory affairs and non-invasive diagnostics expertise.

The commercial engine is Iqirvo (elafibranor), an oral dual PPAR \u03b1/\u03b4 agonist discovered and developed internally by GENFIT that received Accelerated Approval from the FDA, EMA and UK MHRA in 2024 for Primary Biliary Cholangitis (PBC) and is commercialized worldwide by Ipsen under a 2021 exclusive licensing deal. Beyond Iqirvo, the R&D portfolio comprises eight programs across multiple stages of development: in ACLF and hepatic encephalopathy, NTZ/G1090N (nitazoxanide reformulation with FDA Orphan Drug Designation), SRT-015 (licensed ASK1 inhibitor), CLM-022 (licensed NLRP3 inflammasome inhibitor) and VS-02-HE (urease inhibitor); in other life-threatening indications, GNS561 (PPT-1 inhibitor for KRAS-mutated cholangiocarcinoma, in Phase 1b/2a) and VS-01-HAC (liposomal platform for hyperammonemic crises in urea cycle disorders, FDA Rare Pediatric Disease designation); and in diagnostics, NIS4/NIS2+ blood-based biomarker algorithms for at-risk NASH/MASH (commercially available via Labcorp as NASHnext) plus a prototype TS-01 point-of-care ammonia device. The portfolio is backed by 1,000+ patents.

GENFIT monetizes primarily through licensing royalties and milestone payments rather than direct sales. FY2025 revenue was \u20ac65.4 million, comprised of \u20ac21.8 million in royalties on Ipsen's $208 million of Iqirvo net sales and \u20ac43.6 million in milestone payments (including a \u20ac17 million performance milestone and a \u20ac26.5 million Italy pricing/reimbursement milestone). Go-to-market is via channel partners: Ipsen for Iqirvo commercialization globally and Labcorp for the NIS4/NASHnext diagnostic. The company held \u20ac101.1 million in cash at year-end 2025 (\u20ac136.1 million as of March 31, 2026 after activating an additional \u20ac30 million HCRx royalty-financing tranche in January 2026), with stated cash runway extending beyond end of 2028 despite an \u20ac86.0 million FY2025 net loss driven in part by a \u20ac46.2 million non-cash impairment tied to the September 2025 discontinuation of the VS-01 ACLF program.

GENFIT firmographics

Firmographics
Name
GENFIT
Legal name
GENFIT SA
Website
https://genfit.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
GENFIT SA is a France-based, Euronext Paris-listed biopharmaceutical company that develops therapies and diagnostics for rare and life-threatening liver diseases, generating revenue primarily through royalties and milestones from Ipsen's commercialization of Iqirvo (elafibranor) for Primary Biliary Cholangitis.
Ownership category
akta.pro rank

GENFIT industry classification

Industry
Product category
Liver Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Liver disease therapeutics
  • Rare disease biopharmaceuticals
  • Non-invasive diagnostics
  • Biomarker algorithm testing
  • Clinical stage drug development

Where GENFIT is headquartered

Location

Headquarters

HQ city
Loos
HQ country
France
HQ region
Europe

Offices6 records

Markets served

GENFIT business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Royalties from Iqirvo Sales: GENFIT receives royalty revenue from Ipsen's sales of Iqirvo (elafibranor) for Primary Biliary Cholangitis. In 2025, royalty revenue was €21.8 million, up from €2.7 million year-over-year.
  2. Milestone Payments: One-time payments triggered by clinical, regulatory, or commercial milestones. In 2025, GENFIT received €43.6 million in milestone payments, including a €17 million milestone triggered by Ipsen's strong Iqirvo performance, and a €26.5 million milestone for pricing/reimbursement approval in Italy.
  3. Royalty Financing Agreement: GENFIT activated an additional €30 million tranche under its royalty-financing agreement with HCRx in January 2026, extending cash runway beyond end of 2028.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

GENFIT product offering

Product offering

Core offering

GENFIT is a biopharmaceutical company that discovers, develops, and commercializes therapeutic drug candidates and non-invasive diagnostic technologies for rare and life-threatening liver diseases. Its commercial offering includes Iqirvo (elafibranor), a dual PPAR α/δ agonist approved for Primary Biliary Cholangitis in 2024 and marketed by Ipsen, plus the NIS4/NIS2+ blood-based diagnostic biomarkers for NASH/MASH identification (commercialized as NASHnext via Labcorp). The development pipeline targets Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma, urea cycle disorders, and hepatic encephalopathy through multiple proprietary mechanisms.

Product overview

GENFIT is a biopharmaceutical company focused on rare, life-threatening liver diseases. Its product portfolio comprises therapeutic drug candidates across multiple development stages and a diagnostic franchise. The therapeutic pipeline includes Iqirvo® (elafibranor), a dual PPAR α/δ agonist for Primary Biliary Cholangitis (PBC) now commercialized by Ipsen following FDA/EMA/MHRA approval in 2024, and multiple investigational programs for ACLF and associated conditions: G1090N (NTZ reformulation), SRT-015 (ASK1 inhibitor), CLM-022 (NLRP3 inflammasome inhibitor), and VS-02-HE (urease inhibitor for hepatic encephalopathy), all in preclinical or early clinical stages. The diagnostics franchise includes NIS4® and NIS2+®, non-invasive blood-based biomarker technologies for identifying at-risk NASH/MASH patients (commercially available as NASHnext® via Labcorp), and TS-01, a prototype point-of-care device for blood ammonia measurement. Additional therapeutic programs target cholangiocarcinoma (GNS561 in Phase 1b/2a) and urea cycle disorders (VS-01-HAC in preclinical). The company's pipeline covers eight programs across ACLF, other life-threatening indications, and diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • NIS4: Non-invasive blood-based molecular diagnostic technology for identifying patients with at-risk NASH/MASH with NAS≥4 and significant fibrosis F≥2
  • NIS2+
  • TS-01
  • Iqirvo

Products and services

  • Iqirvo (elafibranor) A dual PPAR α/δ agonist originally discovered and developed by GENFIT for treatment of Primary Biliary Cholangitis (PBC). Received Accelerated Approval from FDA, EMA, and MHRA in 2024 and is commercialized by Ipsen in the US and several European countries under a global licensing agreement.
  • NIS4 First-generation blood-based molecular diagnostic technology integrating four NASH/MASH-associated biomarkers (alpha-2-macroglobulin, YKL-40, hemoglobin A1c, miR-34a-5p) through an algorithm to produce a single score for identifying patients with at-risk NASH/MASH. Commercially available as NASHnext via Labcorp.
  • NIS2+ Optimized blood-based molecular diagnostic technology demonstrating robust improved clinical performance for efficient identification of at-risk NASH/MASH regardless of patient characteristics such as age, sex, and type 2 diabetes.
  • TS-01 Point-of-care diagnostic device based on transmembrane pH-gradient polymersome technology for at-home measurement of ammonia in blood, designed to be fast, selective, and sensitive across a wide range covering physiological and pathological ammonia levels.
  • G1090N (NTZ reformulation) A new reformulation of nitazoxanide (NTZ) being developed for Acute-on-Chronic Liver Failure (ACLF), with anti-inflammatory and anti-apoptotic properties targeting gut microbiota and bacterial overgrowth, designed to optimize dose-response and provide dosing flexibility for ACLF patients with renal or hepatic impairment.
  • SRT-015 An ASK1 (Apoptosis Signal-Regulating Kinase 1) inhibitor with injectable formulation licensed exclusively worldwide from Seal Rock Therapeutics in May 2023 for acute liver disease including ACLF. Preclinical and clinical evidence supports multi-system benefits including blocking hyper-inflammatory response, reducing ROS-related immune response, reducing apoptosis, and protecting macrophages.
  • CLM-022 A first-in-class NLRP3 (nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3) inflammasome inhibitor licensed exclusively worldwide from Celloram Inc. in July 2023 for liver disease applications, showing promise in animal models for reducing liver damage and inflammation.
  • VS-02-HE A hydroxamic acid derivative designed as a urease inhibitor to treat Hepatic Encephalopathy (HE), a common complication of ACLF, developed as a unique oral and colon-active formulation designed to minimize systemic absorption of ammonia and reduce glutamine levels in the brain.
  • VS-01-HAC A liposomal therapeutic candidate based on proprietary scavenging liposomal technology administered directly into the peritoneal cavity following drainage of ascites, being developed as a potential first-line lifesaving treatment for acute hyperammonemic crises associated with Urea Cycle Disorders (UCD) and Organic Acidemias (OA). Granted Rare Pediatric Disease designation by the FDA.
  • GNS561 in CCA A Palmitoyl Protein Thioesterase-1 (PPT-1) inhibitor in-licensed from Genoscience Pharma in 2021 that blocks cancer cell proliferation by inhibiting late-stage autophagy, being evaluated in a Phase 1b/2a trial combined with trametinib for KRAS-mutated cholangiocarcinoma. FDA Orphan Drug Designation obtained.

Quantifiable outcome

  • Iqirvo generated $208M in net sales by Ipsen in 2025, triggering $20M milestone payment to GENFIT one year ahead of schedule
  • +3 more outcomes

Companies that use GENFIT

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles2 records

GENFIT technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

GENFIT partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered strategic and core.

  • EF CLIFstrategicStrategic or Co-development Partner · 1 January 2026Co-hosting annual ACLF Insights event at EASL Congress 2026. Collaboration on landmark global consensus meeting to forge unified definition of ACLF.
  • Celloram Inc.strategicTechnology or Integration · 1 July 2023Exclusive worldwide licensing of CLM-022, a first-in-class NLRP3 inflammasome inhibitor for liver disease applications.
  • Seal Rock TherapeuticsstrategicTechnology or Integration · 1 May 2023Exclusive worldwide licensing of SRT-015 (ASK1 inhibitor) for injectable formulation in acute liver disease including ACLF treatment (21 consecutive days or less).
  • Versantis AGcoreStrategic or Co-development Partner · 1 September 2022Acquisition completed in 2022 for CHF 40 million upfront (~$41 million) plus up to CHF 65 million in milestones. Swiss clinical-stage biotech focused on liver diseases, bringing VS-01 liposomal technology and VS-02 urease inhibitor programs. Total potential deal value of CHF 105 million.
  • IpsencoreChannel Partner/ Reseller/ Distributor · 17 June 2021Exclusive global licensing agreement for elafibranor (Iqirvo) for Primary Biliary Cholangitis. Ipsen commercializes the drug in the US, Europe, and other markets. Ipsen also became an 8% shareholder in GENFIT in 2021. Ipsen initiated the only global Phase 3 trial (ELASCOPE2) for PSC in February 2026.
  • LabcorpcoreChannel Partner/ Reseller/ Distributor · 1 January 2021Agreement to commercialize NASHnext, powered by GENFIT's proprietary NIS4 diagnostic technology for identifying at-risk NASH/MASH.
  • Genoscience PharmacoreTechnology or Integration · 1 January 2021Exclusive licensing of GNS561 (PPT-1 inhibitor) for cholangiocarcinoma treatment. GNS561 blocks cancer cell proliferation by inhibiting late-stage autophagy.

Scale indicators20 records

Recent moves8 records

Expansion highlights6 records

GENFIT competitors and assessment

Company assessment

Emerging players

  • 89bio: Clinical-stage biopharma focused on MASH with lead asset pegozafermin (FGF21 analog) in Phase 3. Comparable in therapeutic-area focus and size to GENFIT, with similar specialization in liver metabolic diseases.
  • Terns Pharmaceuticals: Clinical-stage biopharma developing oral therapies for MASH and other chronic liver diseases. Overlaps with GENFIT's hepatology and biomarker-based diagnostic positioning, addressing similar fibrotic and metabolic liver indications.
  • Pliant Therapeutics: Clinical-stage biopharma focused on integrin-based therapies for fibrotic diseases including liver fibrosis and PSC, intersecting with GENFIT's liver fibrosis and cholestatic disease focus.
  • Enyo Pharma: European clinical-stage biopharma developing therapeutics for hepatitis B and acute liver diseases. Comparable in size and European origin to GENFIT, addressing overlapping liver disease therapeutics.

Direct peers

  • Inventiva SA: French late-stage clinical biopharmaceutical company developing therapeutics for liver diseases, including lead asset lanifibranor for MASH. Direct fellow French liver-focused biotech comparable in size, stage, and therapeutic-area focus to GENFIT.
  • Intercept Pharmaceuticals: Maker of Ocaliva (obeticholic acid), the first FDA-approved therapy for Primary Biliary Cholangitis. Direct competitor to GENFIT's Iqirvo in PBC with similar orphan-liver-disease positioning.
  • Madrigal Pharmaceuticals: US biopharma that developed Rezdiffra (resmetirom), the first FDA-approved therapy for MASH with moderate-to-advanced fibrosis. Direct peer in the hepatology space and overlapping biomarker/diagnostic themes relevant to NIS4/NIS2+.

Broad incumbents

  • Gilead Sciences: Global biopharmaceutical leader with broad hepatology presence, including recent acquisition of CymaBay Therapeutics (seladelpar for second-line PBC). Competes broadly with GENFIT in liver disease and now markets a direct PBC competitor to Iqirvo.
  • Ipsen: Global specialty biopharma that is GENFIT's commercialization partner for Iqirvo and an 8% shareholder. Operates a broader hepatology and rare-disease portfolio (including Albireo) overlapping GENFIT's PBC and ACLF focus.

Others

  • BioMarin Pharmaceutical: Independent global rare-disease biopharma with a similar 'small commercial-stage plus specialty pipeline' business model and focus on orphan drug commercialization. Comparable as a strategic model archetype for GENFIT's pursuit of rare-disease and orphan pricing economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

GENFIT social profiles

Digital presence

GENFIT compliance and trust

Trust signal

Compliance1 record

GENFIT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GENFIT leadership team

Management profile

Number of profiles

Profiles8 records

GENFIT subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GENFIT funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GENFIT M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GENFIT

What does GENFIT do?

GENFIT is a biopharmaceutical company that discovers, develops, and commercializes therapeutic drug candidates and non-invasive diagnostic technologies for rare and life-threatening liver diseases. Its commercial offering includes Iqirvo (elafibranor), a dual PPAR α/δ agonist approved for Primary Biliary Cholangitis in 2024 and marketed by Ipsen, plus the NIS4/NIS2+ blood-based diagnostic biomarkers for NASH/MASH identification (commercialized as NASHnext via Labcorp). The development pipeline targets Acute-on-Chronic Liver Failure (ACLF), cholangiocarcinoma, urea cycle disorders, and hepatic encephalopathy through multiple proprietary mechanisms.

Is GENFIT a public or private company?

GENFIT is a public company. It is classified as public and is currently operating.

When was GENFIT founded?

GENFIT was founded in 1999. It employs 101 to 250 people.

Where is GENFIT based?

GENFIT is headquartered in Loos, France, in the Europe region.

How does GENFIT make money?

Three revenue lines are on record. Royalties from Iqirvo Sales are the primary driver. The others are milestone Payments and royalty Financing Agreement.

Who are GENFIT's main competitors?

Emerging players on record are 89bio, Terns Pharmaceuticals, Pliant Therapeutics and Enyo Pharma. Direct peers are Inventiva SA, Intercept Pharmaceuticals and Madrigal Pharmaceuticals. Broad incumbents are Gilead Sciences and Ipsen. BioMarin Pharmaceutical is listed as an others.

Does GENFIT have an API?

No public API is recorded for GENFIT.

What industry is GENFIT in?

GENFIT's product category is Liver Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNombre d’actions et de droits de vote composant le capital socialSA GENFIT disclosed its share capital on October 31, 2026, listing 50,101,194 shares and 56,287,784 voting rights. The company is a French société anonyme with a capital of €12,525,298.50, headquartered in Loos.GlobeNewswireDisclosure of the Total Number of Voting Rights and Shares Forming the Share CapitalSA GENFIT disclosed its total voting rights and shares forming the share capital on October 31, 2026. The company holds 50,101,194 shares and 56,287,784 voting rights, with a capital of €12,525,298.50.MarketScreenerGenfit targets Phase 2a by year-end 2026 for NangibotideGenfit presented Nangibotide at AASLD, targeting Phase 2a by year-end 2026 for acute-on-chronic liver failure. The drug's safety and efficacy database covers 416 patients across three Phase 2 trials, with reduced SOFA scores in septic shock and favorable mortality trends.Business & FinancialGENFIT Highlights Data From Clinical Studies Of Nangibotide, Supporting Its Advancement Into ACLF With Phase 2 Data Expected In 2027GENFIT unveiled nangibotide data at AASLD The Liver Meeting, supporting its Phase 2 development in acute-on-chronic liver failure. The drug showed efficacy signals in prior Phase 2 studies, and a Phase 2a trial is planned to start by end of 2026 with data expected in 2027.GlobeNewswireGENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027GENFIT presented nangibotide Phase 2 data at the AASLD The Liver Meeting, citing safety and efficacy signals in septic shock and severe COVID-19. The company plans a Phase 2a proof-of-concept study (UPWARD) starting late 2026, with results expected in the second half of 2027.GlobeNewswireGENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027GENFIT unveiled nangibotide data supporting its Phase 2 development in acute-on-chronic liver failure (ACLF) at AASLD The Liver Meeting. The drug has shown safety and efficacy signals in prior Phase 2 trials, and a Phase 2a proof-of-concept trial is planned to start by end of 2026 with data expected in 2027.FinancialContent Business PageGENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027GENFIT unveiled nangibotide data at AASLD The Liver Meeting, supporting its Phase 2 development in acute-on-chronic liver failure. The drug showed efficacy signals in prior Phase 2 studies, and a Phase 2a trial is expected to start by end of 2026 with data in 2027.Business & FinancialGENFIT Reports Third Quarter 2026 Financial Information And Provides Corporate UpdateGENFIT reported Q3 2026 revenue of €36.4 million, down from €39.2 million in the prior year, with royalty revenue rising 188% to €36.3 million. Iqirvo net sales grew 125% to €109.4 million in Q3, and regulatory submission for a PBC label update is underway.GlobeNewswireGENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026GENFIT announced its program at AASLD The Liver Meeting 2026, highlighting progress in ACLF and MASH diagnostics. The company will present nangibotide's Phase 2 advancement and NIS technology for non-invasive MASH testing. It also plans a NACSELD meeting and a Beyond the Biopsy forum.GlobeNewswireGENFIT présentera ses avancées dans l’ACLF et dans le diagnostic de la MASH lors du congrès AASLD The Liver Meeting® 2026GENFIT will present its ACLF and MASH diagnostic advances at the AASLD The Liver Meeting 2026, including nangibotide's Phase 2 program. The company will also showcase its NIS diagnostics and host a NACSELD meeting. The event aims to accelerate development and improve patient identification.